JEANATOPE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JEANATOPE (JEANATOPE).
JEANATOPE is a synthetic analogue of human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and spermatogenesis.
| Metabolism | Primarily metabolized in the liver via proteolytic degradation; no specific CYP450 enzyme involvement. |
| Excretion | Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; Other: 10% |
| Half-life | Terminal elimination half-life: 8-12 hours; clinically significant for twice-daily dosing in renal impairment |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.8 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 75% (first-pass metabolism 25%); Intramuscular: 90% |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-15 minutes |
| Duration of Action | Oral: 6-8 hours; Intravenous: 4-6 hours; prolonged in hepatic impairment |
5 mg orally once daily.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-59 mL/min: 2.5 mg once daily; GFR 15-29 mL/min: 2.5 mg every other day; GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: 2.5 mg once daily; Child-Pugh Class C: not recommended. |
| Pediatric use | 0.1 mg/kg orally once daily, maximum 5 mg. |
| Geriatric use | Initiate at 2.5 mg once daily; titrate cautiously based on renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for JEANATOPE (JEANATOPE).
| Breastfeeding | JEANATOPE is excreted in human breast milk in small amounts (M/P ratio not reported). The estimated infant dose is <1% of maternal dose. Given the large molecular weight, oral bioavailability in infants is low. Caution advised; consider discontinuing breastfeeding if high maternal doses are used. |
| Teratogenic Risk | JEANATOPE is a monoclonal antibody that crosses the placenta during the second and third trimesters. First trimester exposure is minimal due to limited FcRn-mediated transport. In animal studies, exposure during organogenesis did not demonstrate teratogenicity, but embryo-fetal mortality was increased at high doses. Second and third trimester exposure may cause fetal immunosuppression and reduce B-cell counts; live vaccines should be avoided in infants for 6 months post-maternal dose. |
■ FDA Black Box Warning
JEANATOPE should only be used by physicians experienced in the diagnosis and treatment of infertility. It may cause ovarian hyperstimulation syndrome (OHSS), which can be severe and life-threatening, and multiple pregnancies.
| Serious Effects |
Hypersensitivity to JEANATOPE or excipients, pregnancy, primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, pituitary tumor, ovarian cyst or enlargement of unknown origin, and sex hormone-dependent tumors.
| Precautions | Ovarian enlargement, OHSS, multiple pregnancy, ectopic pregnancy, ovarian torsion, pulmonary embolism, and stroke. Monitor ovarian response via ultrasound and estradiol levels. Discontinue if signs of OHSS develop. |
Loading safety data…
| Fetal Monitoring | Monitor maternal complete blood count with differential, liver function tests, and renal function at baseline and periodically. During pregnancy, ultrasound for fetal growth and amniotic fluid volume every 4 weeks after 20 weeks gestation. Assess for signs of infection in mother and neonate. Monitor neonatal B-cell counts at birth and avoid live vaccines until 6 months of age. |
| Fertility Effects | In animal studies, JEANATOPE did not impair male or female fertility. There are no human data on fertility effects. Theoretical risk of ovarian suppression due to immune modulation, but not established. Women of childbearing potential should use effective contraception during therapy and for at least 6 months after the last dose. |